ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% – Should You Buy?

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) were up 8% during mid-day trading on Thursday . The company traded as high as $8.70 and last traded at $8.5350. Approximately 493,047 shares traded hands during trading, a decline of 66% from the average daily volume of 1,452,389 shares. The stock had previously closed at $7.90.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Zacks Research raised shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Leerink Partners set a $26.00 target price on ARS Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $29.33.

ARS Pharmaceuticals Stock Performance

The firm’s fifty day moving average is $9.37 and its 200 day moving average is $9.76. The firm has a market capitalization of $838.09 million, a price-to-earnings ratio of -4.82 and a beta of 0.78. The company has a debt-to-equity ratio of 1.47, a current ratio of 7.28 and a quick ratio of 7.06.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share for the quarter, meeting the consensus estimate of ($0.42). The firm had revenue of $28.09 million for the quarter, compared to analyst estimates of $25.58 million. ARS Pharmaceuticals had a negative net margin of 203.25% and a negative return on equity of 100.29%. On average, analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors have recently bought and sold shares of SPRY. Ameritas Investment Partners Inc. raised its stake in shares of ARS Pharmaceuticals by 16.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock valued at $98,000 after acquiring an additional 777 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock worth $56,000 after purchasing an additional 982 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in ARS Pharmaceuticals by 3.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company’s stock worth $596,000 after purchasing an additional 1,234 shares during the period. ProShare Advisors LLC grew its holdings in ARS Pharmaceuticals by 11.3% during the fourth quarter. ProShare Advisors LLC now owns 15,139 shares of the company’s stock valued at $176,000 after purchasing an additional 1,532 shares during the last quarter. Finally, Belpointe Asset Management LLC grew its holdings in ARS Pharmaceuticals by 8.9% during the third quarter. Belpointe Asset Management LLC now owns 18,860 shares of the company’s stock valued at $190,000 after purchasing an additional 1,537 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.